Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of hepatitis C drug developer Inhibitex (Nasdaq: INHX ) felt ill today, with shares down as much as 17%, over continued safety concerns with its drug INX-189.
So what: Last month, rival Pharmasset (Nasdaq: VRUS ) reported some safety issues with its own similar drug, crushing others in the sector and setting the stage for investor skittishness. This morning's sell-off may be attributed to cautious comments from Bank of America Merrill Lynch analyst Rachel McMinn.
Now what: McMinn said that there could be a lot of downside if safety issues arise, although she believes the risk-reward balance is still positive. Inhibitex is conducting a study to evaluate different dosages, and the interim results of the study are expected within this month or next. Shareholders are anxious that INX-189 may share too many similarities with Pharmasset's PSI-938.
Interested in more info on Inhibitex? Add it to your watchlist.